Pharmaceutical

Vicore licenses idiopathic pulmonary fibrosis therapy to Nippon in Japan

Nippon will pay $10m upfront and up to $275m in milestone-based payments for the developmental and commercial rights to Vicore’s C21 in Japan.

Feb 10, 2024 - 18:00
Vicore licenses idiopathic pulmonary fibrosis therapy to Nippon in Japan
Nippon will pay $10m upfront and up to $275m in milestone-based payments for the developmental and commercial rights to Vicore’s C21 in Japan.
Read the original article

Tags:

Previous Article

US Senate committee interrogates big pharma on “outrageously high” drug prices

Next Article

Another recall: does Philips have a quality control problem?

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

AI and stable funding environments are catalysts for biotech assets

AI and stable funding environments are catalysts for bi...

Jun 28, 2024

Merck is on the lookout for more opportunities within immunology

Merck is on the lookout for more opportunities within i...

Jan 29, 2024

Opinion: Value-based payments are making it harder to see your primary care doctor on short notice

Opinion: Value-based payments are making it harder to s...

Sep 20, 2023